Holger N Lode

23PUBLICATIONS
94CO-AUTHORS
Radiation therapyGene and molecular therapyHaematological tumoursNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Sep 13, 2025
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode, Przemysław Holko, Aleksandra Wieczorek

|Aug 14, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Sascha Troschke-Meurer, Maxi Zumpe, Peter Moritz Ahrenberg

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Jun 13, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Steven G DuBois, Lucas Moreno, John Anderson

|Jun 03, 2025
Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

Aleksandra Wieczorek, Katarzyna Śladowska, Holger N Lode

|Jan 11, 2025
Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.

Tim Flaadt, Jonas Rehm, Thorsten Simon

Pageof 4

Frequent Collaborators

10 joint publications

Sascha Troschke-Meurer

6 joint publications

Maxi Zumpe

6 joint publications

Nikolai Siebert

3 joint publications

Thorsten Simon